Literature DB >> 27611615

Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.

Karim J Halazun1, Marc Najjar, Rita M Abdelmessih, Benjamin Samstein, Adam D Griesemer, James V Guarrera, Tomoaki Kato, Elizabeth C Verna, Jean C Emond, Robert S Brown.   

Abstract

OBJECTIVE: We sought to develop a "Model Of Recurrence After Liver transplant" (MORAL) for hepatocellular carcinoma (HCC).
BACKGROUND: The Milan criteria are used to allocate livers to patients with HCC requiring liver transplantation (LT) but do not include objective measures of tumor biology. Biological markers including the neutrophil-lymphocyte ratio (NLR) and alpha-fetoprotein (AFP) have been associated with recurrence risk.
METHODS: Prospective cohort study of adults undergoing LT for HCC between January 2001 and December 2012.
RESULTS: A total of 339 patients were included. On multivariable Cox regression analysis, 3 preoperatively available factors were independent predictors of worse recurrence-free survival (RFS), namely, an NLR ≥ 5 (P < 0.0001, hazard ratio, HR: 6.2), AFP > 200 (P < 0.0001, HR: 3.8), and Size >3 cm (P < 0.001, HR: 3.2). The Pre-MORAL score was constructed from the hazard ratios and assigning patients points in an additive fashion, with a minimum of 0 points (no factors) and a maximum of 13 points (all 3 factors). The highest risk patients in the Pre-MORAL had a 5-year RFS of 17.9% compared with 98.6% for the low risk group (P < 0.0001). The post-MORAL was constructed similarly using the 4 postoperatively available independent predictors of worse RFS, grade 4 HCC's (P < 0.0001, HR: 5.6), vascular invasion (P = 0.019, HR: 2.0), size >3 cm (P < 0.0001, HR: 3.2) and number >3 (P = 0.048, HR: 1.8). The pre- and post-MORAL were superior to Milan at predicting recurrence with c-statistics of 0.82 and 0.87, compared with 0.63, respectively. We then combined the scores to produce a combo-MORAL, with a c-statistic of 0.91 for predicting recurrence.
CONCLUSIONS: The MORAL score provides a simple, highly accurate tool for predicting recurrence and risk-stratification pre- and postoperatively.

Entities:  

Mesh:

Year:  2017        PMID: 27611615     DOI: 10.1097/SLA.0000000000001966

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  75 in total

Review 1.  Transplantation for hepatocellular cancer: pushing to the limits?

Authors:  Quirino Lai; Alessandro Vitale
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-14

Review 2.  When to consider liver transplantation in hepatocellular carcinoma patients?

Authors:  Ka Wing Ma; Tan To Cheung
Journal:  Hepat Oncol       Date:  2017-07-06

3.  Twenty years after: from Milan criteria to a "blended" approach.

Authors:  Giovanni Battista Levi Sandri; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-07-21

Review 4.  Deep vein thrombosis during long-term surveillance of patients with liver transplantation.

Authors:  Alice Balaceanu
Journal:  Ir J Med Sci       Date:  2019-03-08       Impact factor: 1.568

Review 5.  Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer.

Authors:  Trevor W Reichman; Chandra S Bhati; Narendra R Battula
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

6.  Striving for decreased post-transplant hepatocellular carcinoma recurrence without excluding potentially curable patients: the utility of tumor biology.

Authors:  Russell Evan Rosenblatt; Karim Jarir Halazun
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

7.  Pre-operative Microvascular Invasion Prediction Using Multi-parametric Liver MRI Radiomics.

Authors:  Giacomo Nebbia; Qian Zhang; Dooman Arefan; Xinxiang Zhao; Shandong Wu
Journal:  J Digit Imaging       Date:  2020-12       Impact factor: 4.056

8.  Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.

Authors:  Neil Mehta; Jennifer L Dodge; John P Roberts; Francis Y Yao
Journal:  Am J Transplant       Date:  2017-12-02       Impact factor: 8.086

Review 9.  Role of inflammatory markers as hepatocellular cancer selection tool in the setting of liver transplantation.

Authors:  Russell E Rosenblatt; Zaid H Tafesh; Karim J Halazun
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-21

10.  Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation.

Authors:  Sunyoung Lee; Kyoung Won Kim; Woo Kyoung Jeong; Myeong-Jin Kim; Gi Hong Choi; Jin Sub Choi; Gi-Won Song; Sung-Gyu Lee
Journal:  Eur Radiol       Date:  2019-08-30       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.